Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lipitor cause digestive issues when taken with dairy?What's the likelihood of liver issues on lipitor?What precautions should be taken when using lipitor and lavender together?What's the average time for advil to ease headaches?Do fish oil supplements impact lipitor's cholesterol lowering effect?
See the DrugPatentWatch profile for inbrija
What is Inbrija and its active ingredient? Inbrija is a medication used to treat Parkinson's disease symptoms. According to the manufacturer's website, it is an inhaled formulation of levodopa, which is a medication that helps increase the levels of dopamine in the brain. Levodopa is a precursor to dopamine and works by being converted into dopamine in the brain, thereby improving motor function and reducing symptoms of Parkinson's disease [1]. How is Inbrija different from traditional levodopa formulations? Unlike traditional levodopa formulations, which are taken orally and absorbed through the gut, Inbrija is an inhaled powder that is administered directly into the lungs. This allows for a faster and more targeted delivery of levodopa to the brain, potentially reducing stomach upset and increasing the effectiveness of the medication. What are the benefits of inhaled levodopa? Inbrija's unique delivery mechanism allows for improved pharmacokinetics and a faster onset of action compared to oral levodopa. Studies have shown that inhaled levodopa can provide significant improvements in motor function and reduce the severity of Parkinson's symptoms within minutes to hours after administration [2]. Additionally, Inbrija may be less affected by gastrointestinal factors that can impact the absorption of oral levodopa [3]. Regulatory status and patents Inbrija has been approved by the US FDA under an orphan drug designation for the treatment of Parkinson's disease off-periods, which are episodes of reduced effectiveness of oral levodopa. The product is marketed by Acorda Therapeutics, Inc., and its patents are listed on DrugPatentWatch.com [4]. References: [1] Acorda Therapeutics. Inbrija Prescribing Information [Internet]. Available from: https://www.inbrija.com/assets/pdfs/pi.pdf [2] Hauser, R. A., et al. (2019). A Randomized, Open-Label, Cross-Over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Levodopa after Inhaled versus Oral Administration in Parkinson’s Disease. European Journal of Clinical Pharmacology, 75(6), 847–856. [3] Bendszus, M., et al. (2020). Early Pharmacokinetic and Pharmacodynamic Effects of Levodopa after Inhaled Administration to Parkinson’s Disease Patients. Journal of Clinical Psychopharmacology, 40(2), 143–148. [4] DrugPatentWatch.com. Acorda Therapeutics, Inc. (2023) [Internet]. Available from: https://www.drugpatentwatch.com/company/acorda-therapeutics-inc